anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In recent years, there has been a growing focus on using herbal extracts as immune enhancers for aquatic species, replacing antibiotics. In the present study, the effects of dietary supplementation of Hericium erinaceus extract (HE) on growth, feed utilization, hematology, expression of immunity-related genes, and immune responses in Nile tilapia infected by Streptococcus agalactiae were examined. A total of 240 Nile tilapia with an average body weight of 17.28 ± 0.01 g were fed diets enriched with different levels of HE: 0 (HE0), 0.1 (HE0.1), 1.0 (HE1.0), and 5.0 (HE5.0) g/kg. The results showed that growth parameters, feed conversion ratio, and organosomatic indexes were not linearly or quadratically affected by HE supplementation. Fish fed HE0.1 and HE1.0 increased protein efficiency ratio and protein productive values with significant linear and quadratic effects of HE enrichment. In addition, dietary supplementation of HE quadratically increased whole-body protein content. Red blood cell, white blood cell, and hematocrit were linearly and quadratically increased by HE supplementation. HE also linearly and quadratically decreased LDL cholesterol and linearly decreased the total cholesterol levels. Stress markers, serum glucose, and cortisol levels were linearly and/or quadratically decreased in HE-fed fish. The relative mRNA expression of tnf-α, il-1β, il-6, and il-10 were upregulated in the HE0.1 and HE1.0 groups, while dietary supplementation of HE significantly decreased hsp70cb1 mRNA expression in all groups. After feeding dietary HE supplementation for 10 weeks, fish were intraperitoneally injected with pathogenic S. agalactiae. A high survival after challenge was found in all HE supplementation groups with the highest percent survival observed in the HE1.0 and HE5.0 groups. Our findings represent that supplementation of 1 g/kg of HE (HE1.0) could obtain the greatest effects on immunity and survival of Nile tilapia. In addition, the present study also showed that dietary supplementation of HE can improve protein utilization, hematology, expression of genes related to immunity, stress markers, and resistance of Nile tilapia against pathogenic bacterial infection.
IN THE    CANADIAN           PATENT & TRADEMARK OFFICE PATENT APPLICATION   entitled: Derivatives of 3-imino-pyridazine, process for obtaining them and pharmaceutical composi-tions containing them in the names of: Camille Georges WERMUTH, Gilbert SCHLEWER, Michel HEAULME   assigned to: SANOFI               ABSTRACT OF THE DISCLOSURE      The invention relates to derivatives of 2,3-dihydro 3-imino-pyridazine responding to general formula:     (I)   in which: - A represerts an atom of oxygen or of sulfur; - R1 represents a lower alkyl group, or an aromatic group selected from:      . the phenyl group; . the phenyl groups mono- or poly-substituted by a halogen group, a lower alkyl group, a lower alkoxy group, a nitro group, a hydroxy or methylene-dioxy group;      . the naphthyl group; . the furyl group; . the thienyl group or the pyridyl group; - R2 and R3 each designate independently hydrogen or a lower alkyl group; a phenyl group, or R2 and R3, taken together, constitute, with the 2 atoms of the pyridazinic cycle to which they are bonded, a benzene ring, and their pharmaceutically acceptable salts. Application: antidepressants or psychotonics.
CONCERNS RELATED TO ADVERSE EFFECTS:   
Methemoglobinemia:Has been reported with local anesthetics; clinically significant methemoglobinemia requires immediate treatment along with discontinuation of the anesthetic and other oxidizing agents. Onset may be immediate or delayed (hours) after anesthetic exposure. Patients with G6PD deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, exposure to oxidizing agents or their metabolites, or infants <6 months of age are more susceptible and should be closely monitored for signs and symptoms of methemoglobinemia (including pale, gray, or blue-colored skin (cyanosis), headache, rapid pulse, shortness of breath, lightheadedness, fatigue). 

  
WARNINGS: For external use only. Not for ophthalmic use.

Topical formulations of lidocaine may be absorbed to a greater extent through mucous membranes and abraded, fissured or irritated skin than through intact skin. Product should not be ingested or applied into the mouth, inside of the nose or in the eyes. Product should not be used in the ears. Any situation where lidocaine penetrates beyond the tympanic membrane into the middle ear is contraindicated because of ototoxicity associated with lidocaine observed in animals when instilled in the middle ear. Product should not come into contact with the eye or be applied into the eye because of the risk of severe eye irritation and the loss of eye surface sensation, which reduces protective reflexes and can lead to corneal irritation and possibly abrasion. If eye contact occurs, rinse out the eye immediately with saline or water and protect the eye surface until sensation is restored.
The invention relates to a herbal compound capsule, and particularly to a herbal compound capsule for treating and preventing senile retinopathy and macular degeneration and a use method thereof. The capsule comprises the following main components by percentage: 30% of lutein, 8% of wolfberry fruit, 8% of grifola, 8% of cassia seed, 8% of ligustrum lucidum, 8% of buerger pipewort flower, 8% of rhizoma alismatis, 5% of astragaloside, 5% of ginsenoside, 5% of panax notoginseng saponins, 5% of cordycepin and 2% of carotene. The twelve medicines are ultra-finely grinded, and are evenly mixed to prepare the capsule. The capsule 1.5-2 g is swallowed by boiled water after each meal, and one granule of idebenone is synchronously swallowed; capsule 30 mg is continuously taken for three or four months. During the medication, cigarettes and wine are forbidden, spicy stimulating foods are forbidden, and patients cannot be angry. The capsule is taken by 30 neurodeatrophia and macular hole patients and 5 patients after retina and submacular operations; capsule1.5-2 g is taken orally at each time, and one granule30 mg of idebenone is synchronously taken; the medicines are taken for three times per day, and are continuously taken for three or four months; all patients obtain satisfactory effect, and subjective symptoms, such as blurred vision, dryness of two eyes, photophobia, tearing, swelling of eyes, and ophthalmalgia are obviously improved. And the naked vision is improved.
The poly(pro-drug) material includes one or more alternating therapeutic compounds and biodegradable hydrocarbyl groups. The therapeutic compounds and biodegradable hydrocarbyl groups are separated by cleavable linker compounds. The therapeutic compounds, such as estrogen, curcumin, and fingolimod, include a plurality of substitutable functional groups that provide reaction sites for complexing with the cleavable linkers and in turn one or more polymers, such that the poly(pro-drug) material ends up composed of the therapeutic compound itself. In aqueous media and at physiological temperature and pH, the poly(pro-drug) materials degrade to release the therapeutic compounds from the material with a zero-order release profile. Advantageously, the poly(pro-drug) materials release the therapeutic compounds on time scales of years. The poly(pro-drug) materials also exhibit reduced to allow for prolonged implantation within a patient. These materials are enticing for a myriad of biomedical applications, including veterinary medicine, cancer treatments, birth control, and hormone replacement therapy.
The τ-subunit of the clamp loader complex physically interacts with both the DnaB helicase and the polymerase III (Pol III) core α-subunit through domains IV and V, respectively. This interaction is proposed to help maintain rapid and efficient DNA synthesis rates with high genomic fidelity and plasticity, facilitating enzymatic coupling within the replisome. To test this hypothesis, CRISPR-Cas9 editing was used to create site-directed genomic mutations within the dnaX gene at the C terminus of τ predicted to interact with the α-subunit of Pol III. Perturbation of the α-τ binding interaction in vivo resulted in cellular and genomic stress markers that included reduced growth rates, fitness, and viabilities. Specifically, dnaX:mut strains showed increased cell filamentation, mutagenesis frequencies, and activated SOS. In situ fluorescence flow cytometry and microscopy quantified large increases in the amount of ssDNA gaps present. Removal of the C terminus of τ (I618X) still maintained its interactions with DnaB and stimulated unwinding but lost its interaction with Pol III, resulting in significantly reduced rolling circle DNA synthesis. Intriguingly, dnaX:L635P/D636G had the largest induction of SOS, high mutagenesis, and the most prominent ssDNA gaps, which can be explained by an impaired ability to regulate the unwinding speed of DnaB resulting in a faster rate of in vitro rolling circle DNA replication, inducing replisome decoupling. Therefore, τ-stimulated DnaB unwinding and physical coupling with Pol III acts to enforce replisome plasticity to maintain an efficient rate of synthesis and prevent genomic instability.
Provided are an acne removal apparatus patch and an acne removal apparatus including the acne removal apparatus patch. The acne removal apparatus patch is attached to an acne removal apparatus to form an acne removal apparatus patch layer so that the acne removal apparatus can be prevented from puncturing the human skin when the acne removal apparatus deep penetrates into pores of the human skin or is in contact with the skin, wherein the acne removal apparatus can be fully or partially wrapped by the acne removal apparatus patch layer. A form of the acne removal apparatus patch layer conforms to the part of the acne removal apparatus to be wrapped. The acne removal apparatus patch layer is assembled in a form of a patch group, that is, a plurality of acne removal apparatus patch layers are combined in a patch material, and the acne removal apparatus patch layers are mounted in the patch material in a form that is easy to separate. The patch material and the plurality of acne removal apparatus patch layers are pasted in a release paper. When in use, the acne removal apparatus patch layers are torn off from the release paper for easy use.
Delayed Onset Muscle Soreness (DOMS) is a common phenomenon experienced after unaccustomed or intense physical activity, characterized by muscle discomfort, pain, and reduced range of motion. Various interventions have been conducted to alleviate DOMS symptoms, including the use of foam rollers and Kinesiology Tape (KT tape).

This randomized controlled clinical trial aims to compare the effects of foam roller and KT tape interventions on reducing DOMS and improving muscle recovery. The participants would go for a single session of High Intensity Interval Training (HIIT) to induce DOMS. Group-A participants would receive KT taping afterwards, while Group-B participants would receive foam rolling as intervention. Their effect would be measured using Visual Analog Scale (VAS), Tenderness Grading Scale, Knee Range of Motion (ROM) and Vertical Jump Height. This study delves into the applications and potential benefits of KT tape and foam roller in managing DOMS, shedding light on their effectiveness and how they can contribute to enhancing post-exercise recuperation and overall well-being.
BACKGROUND: When mother`s own milk (MOM) is unavailable or insufficient, donor milk (DM) from a human milk bank serves as an alternative feeding option. Our study sought to investigate and compare the outcomes and complications of very low birth weight (VLBW) preterm infants who receive MOM versus DM.
METHODS: In this retrospective cohort study conducted between 2018 and 2022, we compared 70 VLBW preterm infants exclusively fed with DM to 70 randomly selected counterparts fed with MOM. Both groups began enteral feeding within 72 hours of birth. Various clinical outcomes were investigated during a three-month follow-up. The clinical outcomes were compared via independent t-tests, Mann-Whitney U, and Fisher`s exact test.
RESULTS: The mean gestational age of the infants who were included was 29.6 ± 1.6 weeks, 84 (60%) were males, and the average birth weight was 1217 ± 151 grams. Both groups had similar baseline characteristics. The results of the study demonstrated no statistically significant differences between the groups in terms of hospital length of stay (37±16.3 days in MOM vs 40.3±16.9 days in DM group, P= 0.17), growth rate (13±4 gram/day in MOM vs 13±4 gram/day in DM group, P=0.51), growth velocity (9.8±3.0g/kg/d in MOM vs 9.5±3.2 g/kg/d in DM group), infants with in-hospital vomiting (51 cases in MOM vs 59 cases in DM group, P=0.15),vomiting frequency (1.3±1.1 times in MOM vs 1.5±1.0 times in DM group), incidence of retinopathy of prematurity (ROP) (4 cases in MOM vs 5 cases in DM group, P > 0.999) and incidence of bronchopulmonary dysplasia (BPD) (7 cases in MOM vs 6 cases in DM group, P > 0.999).
CONCLUSION: Our study findings indicate that the utilization of DM didn`t have a substantial negative impact on infants` outcomes nor any complications in comparison with MOM.
Daily doses by oral administration on each day of each 28 day cycle. Starting dose is 25mg, with escalation to 400mg, and subsequent dose escalation using a modified Fibonacci algorithm.
Nafcillin for Injection, USP is a semisynthetic antibiotic substance derived from 6-amino-penicillanic acid. It is the sodium salt in a parenteral dosage form. The chemical name of nafcillin sodium is monosodium (2S,5R,6R)-6-(2-ethoxy-1-naphthamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate monohydrate. It is resistant to inactivation by the enzyme penicillinase (beta-lactamase). The structural formula of nafcillin sodium is as follows: 

Nafcillin for Injection, USP is a white to yellowish white powder filled in clear glass bottle. Dilute solutions are essentially clear and colorless. 

Nafcillin for Injection, USP is supplied in 10 gram Pharmacy Bulk Package bottles. Each Pharmacy Bulk Package contains nafcillin sodium as the monohydrate equivalent to 10 grams of nafcillin. Sodium citrate is added to optimize pH. The sodium content is not more than 66.2 mg [2.9 mEq] per gram of nafcillin. 

A pharmacy bulk package is a container of a sterile preparation for parenteral use that contains many single doses. The contents of this pharmacy bulk package are intended for use by a pharmacy admixture service for addition to suitable parenteral fluids in the preparation of admixtures for intravenous infusion (see DOSAGE AND ADMINISTRATION, Directions for Proper Use of Pharmacy Bulk Package). FURTHER DILUTION IS REQUIRED. NOT FOR DIRECT INFUSION.
Fiberoptic bronchoscopy is the imaging of the tracheobronchial tree for diagnosis and treatment in lung diseases. The operation performed through the airway is difficult for the patient to tolerate. Therefore, it is recommended to perform the procedure under sedation. With this survey study, it was aimed to determine the sedation protocols preferred by pulmonologists who perform active fiberoptic bronchoscopy throughout Turkey during the procedure.

Thirty questions were determined for the questionnaire to be used as a data collection method by the researchers. The questions generally consist of three parts; In the first part, there are 8 questions containing the personal information of the doctors (age, gender, title, institution, etc.). In the second part, 13 questions were included in order to make a general assessment such as the sedative agents used by the doctors before and during the bronchoscopy procedure, and the satisfaction with the sedative method used. In the third part, 9 questions were given to determine the preferred follow-up methods during the procedure. The questions are designed to be presented to participants over the network using google forms.
A method includes accessing data related to a series of patient events (e.g. medical procedures, diagnoses or medical test results), and determining whether the data accessed is related to a specific condition. Care pathway data for the condition is generated in response to determining that the accessed data is related to the specific condition. The care pathway data for the condition is stored at a custom extension to a relational database. An aspect of the invention includes generating a care pathway shape as a new custom user-defined type (UDT) extension to the SQL Server database. In yet another aspect, the care pathway data for the condition is generated by linking the one or more patient events related to the treatment of the condition. The linked patient events for the treatment of the condition are represented as a single value, and the single value is a care pathway shape. Identifying an effective pathway for the treatment of a particular condition may potentially lead to the development of standardized care pathways for specific conditions.
PROBLEM TO BE SOLVED: To provide a spirulina composition with which an effect for lowering a blood total cholesterol value is furthermore improved.SOLUTION: This spirulina composition includes 100 pts.wt. spirulina powder, 0.04-40 pts.wt. vitamin C (L-ascorbic acid), 0.02-20 pts.wt. plant enzyme powder and 0.01-10 pts.wt. sporogenous lactobacillus powder. Vitamin C is constituted of L-ascorbic acid. The plant enzyme powder is enzyme powder produced by slicing and fermenting a raw material as it is such as oligosaccharide, unrefined sugar, sucrose, Chenopodium, Mallotus japonicus, Gynostemma pentaphyllum, ginkgo leaves, araliad, curcuma, Acanthopanax senticosus Harms or Cassia obtusifolia, or by adding saccharides thereto, followed by fermentation and maturation thereof, and then drying a stock solution obtained by filtering them. The sporogenous lactobacillus powder is preferably Lacris bacteria powder.
Patients are instructed to consume 20g of whey protein in the morning and 20g at night, during 15 days, as a supplement. Their regular usual diet is maintained.
BACKGROUND/AIM: This study aimed to investigate the role of transient receptor potential vanilloid 2 (TRPV2) in a mouse model with non-alcoholic steatohepatitis (NASH) and to examine the effects of tranilast on TRPV2 and fibrosis-related cytokines.
MATERIALS AND METHODS: C57BL/6N mice were fed a Gubra-Amylin NASH (GAN) diet for 20 weeks to induce NASH. The tranilast groups received oral administration of tranilast at doses of 300, 400 and 500 mg/kg/day, five days per week for 20 weeks, in addition to the GAN diet. The effects of tranilast were assessed based on the dosage of food intake, changes in body weight, liver weight, blood biochemical parameters, histopathological examination, and expression of TRPV2 and inflammatory cytokines.
RESULTS: Hepatic expression of TRPV2 was observed in the GAN-fed NASH mouse model. The tranilast groups showed significantly suppressed increases in body and liver weights. The development of intrahepatic fat deposition and liver fibrosis, assessed histopathologically, was inhibited. Tranilast administration improved the expression of TRPV2 and inflammatory cytokines in the liver. Additionally, blood tests indicated a reduction in elevated liver enzyme levels.
CONCLUSION: In GAN diet NASH models, TRPV2 was up-regulated in the liver and tranilast inhibited TRPV2 and suppressed fibrosis. Therefore, it might prevent the incidence of hepatocellular carcinoma associated with NASH.
The instant disclosure relates to methods for treating chemically relaxed hair. The methods include applying a neutralizing composition to the chemically relaxed hair, the neutralizing composition comprising: at least 0.5 wt. % of at least one carboxylic acid, one or more C 2 -C 6  monoalkanolamines, and water. The neutralizing composition is allowed to remain on the hair for a period of time. The hair is also treated with a neutralizing conditioner, which is a different than the neutralizing composition. The neutralizing conditioner includes: at least 0.5 wt. % of at least one carboxylic acid, one or more C 2 -C 6  monoalkanolamines, one or more cationic surfactants, and water. The neutralizing conditioner is allowed to remain on the hair for a period of time. After treatment with a neutralizing composition and a neutralizing conditioner, the hair may be further treated with a shampoo, a conditioner, a conditioning shampoo, etc., dried, and/or styled.
Clinical follow-up studies of 316 newborns of women administered cetrorelix acetate for injection were reviewed. One infant of a set of twin neonates was found to have anencephaly at birth and died after four days. The other twin was normal. Developmental findings from ongoing baby follow-up included a child with a ventricular septal defect and another child with bilateral congenital glaucoma.

Four pregnancies that resulted in therapeutic abortion in Phase 2 and Phase 3 controlled ovarian stimulation studies had major anomalies (diaphragmatic hernia, trisomy 21, Klinefelter syndrome, polymalformation, and trisomy 18). In three of these four cases, intracytoplasmic sperm injection (ICSI) was the fertilization method employed; in the fourth case, in vitro fertilization (IVF) was the method employed.

The minor congenital anomalies reported include: supernumerary nipple, bilateral strabismus, imperforate hymen, congenital nevi, hemangiomata, and QT syndrome.

The causal relationship between the reported anomalies and cetrorelix acetate for injection is unknown. Multiple factors, genetic and others (including, but not limited to ICSI, IVF, gonadotropins, and progesterone) make causal attribution difficult to study.
Background: The prevalence of metabolic syndrome (MetS) in Kazakhstan reaches 40%. The presence of an association between certain genetic markers and the development of MetS will allow more accurately determining the cardiovascular risk for patients with hypertension and personalizing preventive recommendations. Methods: The purpose of the study was to investigate the presence of an associative relationship between various polymorphisms of the α-synuclein gene and the development of MetS in Kazakh people with high blood pressure. Four hundred twenty-six patients were examined [age 49.5 (interquartile range 42.5-56), men 209 (49.1%), women 217 (50.9%)]. Standard clinical and laboratory methods were used. AutoMate Express™ and OpenArray technologies were used for DNA extraction and further genotyping. Patients with MetS made up the ms+ group, those without MetS-the ms- group. Results: In the examined patients, four polymorphisms of the α-synuclein gene were identified: rs356219, rs2736990, rs11931074, and rs2737029. According to the results of statistical analysis, the frequency and risk of developing MetS did not depend on different alleles and inheritance types of polymorphisms rs356219 and rs11931074. The minor allele of polymorphism rs2737029 exhibits a higher frequency in patients with arterial hypertension accompanied by MetS, although the specific model of inheritance remains to be conclusively determined. Conclusions: In carriers of the minor allele of polymorphism rs2736990, the risk of MetS increases 1.3 times, regardless of age and gender [odds ratio (95% confidence interval) = 1.36 (1.01-1.82), P < 0.05], the inheritance model is log-additive.
The investigators will use an active sham in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session. This intervention will be optimized to each participant to deliver currents designed to not significantly influence their cortical tissue, but still mimic the cutaneous sensations induced by tDCS.
Paclitaxel 80 mg/m2 weekly for 12 weeks and Trastuzumab 8 mg/kg followed by 6 mg/kg Day 1 every 21 days for 4 cycles. Trastuzumab 6 mg/kg Day 1 every 21 days to complete 1 year of Trastuzumab therapy. Alternatively Trastuzumab 4 mg/kg followed by 2 mg/kg weekly to complete 1 year of treatment can be used.